-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Downgrades Vistagen Therapeutics to Hold, Lowers Price Target to $0.9

Benzinga·12/17/2025 20:36:48
語音播報
Jefferies analyst Andrew Tsai downgrades Vistagen Therapeutics (NASDAQ:VTGN) from Buy to Hold and lowers the price target from $15 to $0.9.